BiotechTube

Placebo Oral Tablet + Roluperidone 32 mg + Roluperidone 64 mg

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Negative Symptoms of Schizophrenia

Conditions

Negative Symptoms of Schizophrenia

Trial Timeline

Dec 15, 2017 → Feb 15, 2021

NCT ID
NCT03397134

About Placebo Oral Tablet + Roluperidone 32 mg + Roluperidone 64 mg

Placebo Oral Tablet + Roluperidone 32 mg + Roluperidone 64 mg is a phase 3 stage product being developed by Minerva Neurosciences for Negative Symptoms of Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03397134. Target conditions include Negative Symptoms of Schizophrenia.

What happened to similar drugs?

3 of 20 similar drugs in Negative Symptoms of Schizophrenia were approved

Approved (3) Terminated (3) Active (15)
✅Zoledronic acid + Standard TherapyNovartisApproved
✅Zoledronic Acid + PlaceboNovartisApproved
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
🔄Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03397134Phase 3Completed

Competing Products

20 competing products in Negative Symptoms of Schizophrenia

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
eFT508eFFECTOR TherapeuticsPhase 2
17
No drugDaiichi SankyoPre-clinical
30
ASP0113 + PlaceboAstellas PharmaPhase 2
35
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Cefiderocol + Standard of CareShionogiPhase 2
35
CefiderocolShionogiPre-clinical
26
Cefiderocol + Standard of CareShionogiPhase 2
35
Cefiderocol + Standard of CareShionogiPhase 2
35
E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
40
Durvalumab + EribulinEisaiPhase 1
29
Eribulin + Cyclophosphamide + DocetaxelEisaiPhase 2
35
eribulin mesylate + carboplatinEisaiPhase 2
31
Abemaciclib + BicalutamideEli LillyPhase 2
42
PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
32
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
40
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44